Monthly Archives: June 2015

Surgical Robots Market is Anticipated to Reach $20 billion by 2021: Global Industry Size, Share, Trends And Forecast to 2021

AcuteMarketReports.com has announced the addition of “Surgical Robots Market Shares, Strategies, and Forecasts, Worldwide, 2015 to 2021” market research report to their database

Pune, India – June 30, 2015 /MarketersMedia/ —

The new study Surgical Robots: Market Shares, Strategy, and Forecasts, Worldwide, 2015 to 2021 has 553 pages, 216 tables and figures. Worldwide surgical robot markets are poised to achieve significant growth as next generation systems provide a way to improve traditional open surgery and decrease the number of ports needed for minimally invasive surgery.

Intuitive Surgical has market leadership position, advanced technology, an impressive installed base and a well trained group of surgeons able to manage the robots. Patients fare better when the surgery is done by surgical robots. The documentation of improvements in care delivery, the ability to ensure better outcomes from surgery promise that surgical robotics is a strong growth market. Intuitive Surgical will be difficult to dislodge, its dominant position is based on technological excellence that keeps being improved and competitors have a difficult time catching up, much less improving on the Intuitive Surgical technology.

Other leading competitors will emerge and the group of several surgical robotic companies will collectively have enough marketing dollars and enough marketing clout to drive replacement of all open surgery. Robotic surgery is positioned to become the standard of care. Intuitive Surgical has achieved market saturation in colorectal surgery in the US, it will work on increasing its presence in other surgical market sectors. The leading robotic surgical companies are poised to grow through acquisition, purchasing smaller companies that have developed as specialized product and gained FDA approval. As detailed in the market research study there are a lot of those in every medical specialty and more to come.

For More Information, Tables, Figures And TOC Visit : http://www.acutemarketreports.com/report/surgical-robots-market

The surgeon performs the procedure while sitting at a console, manipulating the instrument controls and viewing the operation through a vision system. When a surgeon needs to change an instrument the instrument is withdrawn from the surgical field using the controls at the console. This is done many times during an operation.
The companies that get an early foothold in the market have significant strategic advantage. The robotic surgical technique benefits hospitals by reducing the length of patient stays, thereby enabling better cost management. This factor is driving demand for surgery robot systems. Since robotics provide surgeons with a precise, repeatable and controlled ability to perform procedures in tight spaces, they are increasingly in demand.

Surgical robot device markets at $3.2 billion in 2014 are anticipated to reach $20 billion by 2021 as next generation devices, systems, and instruments are introduced to manage surgery through small ports in the body instead of large open wounds. The complete report provides a comprehensive analysis including procedure numbers, units sold, market value, forecasts, as well as a detailed competitive market shares and analysis of major players’ success, challenges, and strategies in each segment and subsegment. The reports cover markets for: medical specialties and sub-specialties.

Browse All Reports of This Category @ http://www.acutemarketreports.com/category/ict-market

Companies Profiled
Market Leaders
Intuitive Surgical Accuray
Stryker / Mako Hansen Medical
Medrobotics Freehand 2010

Market Participants
Accel Spine
Accuray
Aesynt / Health Robotics
Alliance Spine
Alphatec Spine
Amedica
Apollo Spine
Ascendx Spine
AVRA Surgical
Back 2 Basics Spine
Captiva Spine
Centinel Spine
Corindus
Elekta AB
Freehand
Globus Medical
Hansen Medical
Healthcare Robotics Lab
Intuitive Surgical
Johnson and Johnson / DePuy
Synthes
K2M
Lanx / EBI Holdings / BioMet /
LDR
Life Spine
Mazor Robotics
Medrobotics
Medtronic
NLT Spine
NuVasive
Otto Bock HealthCare
RTI Biologics / Pioneer Surgical
Technology
Precision Spine
Restoration Robotics
SI-BONE 503
Spinal Elements
Spineart
SpineGuard
Spine Frontier
Spineology

For more information about us, please visit http://www.acutemarketreports.com/

Contact Info:
Name: Chris Paul
Email: sales@acutemarketreports.com
Organization: Acute Market Reports
Address: Office No 1, 1st Floor , Aditi Mall, Baner, Pune, MH, 411045 India
Phone: 1-855-455-8662

Source: http://marketersmedia.com/surgical-robots-market-is-anticipated-to-reach-20-billion-by-2021-global-industry-size-share-trends-and-forecast-to-2021/85666

Release ID: 85666

Advanced Emissions Solutions Comments on the Ruling from the U.S. Supreme Court

HIGHLANDS RANCH, CO / ACCESSWIRE / June 30, 2015 / Advanced Emissions Solutions, Inc. (OTC: ADES) (the “Company”) commented on the U.S. Supreme Court’s June 29th ruling that the Environmental Protection Agency (“EPA”) must reconsider the Mercury Air Toxics Rule (“MATS”) because it did not properly take into account the costs of the regulations before deciding to adopt them. The decision remands the case back to the U.S. Court of Appeals for the D.C. Circuit.

L. Heath Sampson, President and Chief Executive Officer of the Company stated, “Although this decision is disappointing, the most important unanswered question is whether the D.C. Circuit Court will allow the EPA to keep the regulation in effect until the cost analysis is complete. Until the D.C. Circuit Court concludes on this, the MATS rule is still in effect and will continue to apply. We expect that today’s ruling will have no impact to our Refined Coal business and note that many utilities that use Refined Coal are located in states with their own mercury rules, and further, that many utilities were using Refined Coal well before the MATS rule was enacted. In looking at our other businesses, the ruling may result in delays for some of our MATS compliance products in states without their own mercury rules; however, it is premature to assess until we know what the D.C. Circuit Court will ask of the EPA. The Company looks forward to continuing to help our customers meet both new and existing regulations for a variety of pollutants.”

About Advanced Emissions Solutions, Inc.

Advanced Emissions Solutions, Inc. serves as the holding entity for a family of companies that provide emissions solutions to customers in the power generation and other industries.

ADA-ES, Inc. (“ADA”) supplies Activated Carbon Injection (“ACI”) systems for mercury control, Dry Sorbent Injection (“DSI”) systems for acid gases, and technology services and other offerings in support of our customers’ emissions compliance strategies. ADA’s M-Prove(TM) technology, which reduces emissions of mercury and other metals from PRB coal, is applied directly to coal at power plants, or offered through a licensing agreement with Arch Coal for application at their mines. In addition, we are developing technologies to advance cleaner energy, including CO2 emissions control technologies through projects funded by the U.S. Department of Energy (“DOE”) and industry participants.

Clean Coal Solutions, LLC (“CCS”) is a 42.5% owned joint venture by ADA that provides ADA’s patented Refined Coal (“RC”) CyClean(TM) technology to enhance combustion of and reduce emissions of NOx and mercury from coals in cyclone boilers and ADA’s patent pending M-45(TM) and M-45-PC(TM) technologies for Circulating Fluidized boilers and Pulverized Coal boilers respectively.

Advanced Clean Energy Solutions, LLC (“ACES”) is a wholly owned subsidiary of ADES that is focused on supporting and improving the Company’s existing products and identifying, developing and commercializing new solutions to advance cleaner energy and to help our customers meet existing and future regulatory and business challenges. Building off the success of M-45(TM) and M-45-PC(TM) Technologies for Refined Coal, ACES is currently working to develop and commercialize new technologies to reduce a range of emissions associated with power generation and oil & gas production. ACES has assembled a strong team and follows a rigorous process focused on development and maximizing the return on investment.

BCSI, LLC is a custom designer and fabricator of engineered emissions control technologies, bulk material handling equipment, bulk storage systems, water/waste water treatment equipment, and custom components. BCSI supplies Dry Sorbent Injection (“DSI”) systems for acid gas control using its technologically advanced cool, dry conditioned conveying air systems. BCSI’s technical solutions serve a wide range of industrial clients including; coal fired utilities, water treatment, wastewater, cement kilns, food processing and industrial boilers. BCSI employs engineers and trade professionals at a 190,000+sq. ft. fabrication and office facility located in McKeesport, PA.

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, which provides a “safe harbor” for such statements in certain circumstances. The forward-looking statements include statements or expectations regarding the impact of the U.S. Supreme Court’s ruling on our Refined Coal and other businesses including delays and timing, our ability to help customers meet new and existing regulations and related matters. These statements are based on current expectations, estimates, projections, beliefs and assumptions of the Company’s management. Such statements involve significant risks and uncertainties. Actual events or results could differ materially from those discussed in the forward-looking statements as a result of various factors, including but not limited to, changes in economic conditions or market demand; timing of or changes in laws, regulations, IRS interpretations or guidance and any pending court decisions, legal challenges to or repeal of them; technical and operational difficulties; availability of raw materials and equipment; loss of key personnel; intellectual property infringement claims from third parties; impact of the weather and other factors discussed in greater detail in the Company’s filings with the Securities and Exchange Commission (“SEC”). You are cautioned not to place undue reliance on such statements and to consult the Company’s SEC filings for additional risks and uncertainties that may apply to the Company’s business and the ownership of its securities. The Company’s forward-looking statements are presented as of the date made, and the Company disclaims any duty to update such statements unless required by law to do so.

Graham Mattison
Vice President, Strategic Initiatives and Investor Relations
(720) 889-6206
graham.mattison@adaes.com

SOURCE: Advanced Emissions Solutions, Inc.

ReleaseID: 430254

AAA signe un accord de distribution pour Lutathera(R) au Japon avec Fujifilm RI Pharma, Co., LTD

SAINT-GENIS-POUILLY, FRANCE / ACCESSWIRE / June 30, 2015 / Advanced Accelerator Applications S.A. (AAA), entreprise internationale spécialisée en médecine nucléaire moléculaire (MNM), annonce aujourd’hui qu’elle a conclu un accord de distribution pour le Lutathera(R) au Japon avec Fujifilm RI Pharma, Co., LTD (FRI), un leader de la distribution de produits de médecine nucléaire et d’imagerie diagnostique au Japon. Le Lutathera(R) est actuellement en étude clinique pivot de Phase III en Europe et aux Etats-Unis. Les résultats de l’étude sont attendus pour le troisième trimestre 2015.

Dans le cadre de l’accord, AAA recevra des paiements échelonnés au cours des phases de développement et de lancement en plus de royalties sur les ventes de produits. Le Lutathera(R) sera fabriqué par AAA en Europe et vendu à FRI par l’intermédiaire de la filiale AAA International.

AAA et FRI collaboreront ensemble pour répondre à l’ensemble des exigences réglementaires japonaises et préparer l’approbation du produit à l’échelle nationale.

“Nous nous félicitons d’avoir signé notre premier contrat de distribution pour le Lutathera en Asie avec FRI,” a déclaré Stefano Buono, Directeur Général de AAA. “FRI offre un important réseau de vente, marketing et de distribution pour le Lutathera(R) sur le marché japonais, ainsi que le soutien nécessaire pour obtenir l’autorisation réglementaire au Japon. Nous pensons que l’Asie est un marché significatif pour le Lutathera(R), et le Japon représente une première présence importante pour l’entrée sur ce marché. Notre objectif est de poursuivre la mise en place d’accords de distribution tels que celui de FRI dans les pays où nous n’avons pas de présence directe.”

“Pour les cinq plus grands marchés européens et les Etats-Unis, nous avons pour objectif de mettre en place des structures et équipes commerciales propres à AAA dans chaque pays pour soutenir le lancement et la promotion de Lutathera(R) et de Somakit(R), l’agent diagnostic TEP, compagnon de Lutathera(R) pour lequel nous allons bientôt soumettre un dossier de New Drug Application (NDA) auprès de la FDA américaine,” a ajouté Stefano Buono.

Gérard Ber, COO Groupe de AAA, a déclaré: “Un des objectifs principaux de AAA est de combler le vide thérapeutique existant pour les patients atteints de tumeurs neuroendocrines gastroentéropancréatiques à travers le monde. Nous travaillons activement au développement de la franchise Lutathera(R)et sommes impatients de mettre en place d’autres accords de commercialisation pour d’autres pays et d’offrir une meilleure prise en charge aux patients atteints de cancer à une échelle de plus en plus globale.”

Le Lutathera(R) est actuellement en étude pivot de Phase III pour le traitement des tumeurs neuroendocrines de l’intestin moyen dans 51 centres cliniques aux Etats-Unis et en Europe (l’étude NETTER-1). Le recrutement des patients a été finalisé en février 2015 et le nombre d’événements de progression nécessaires pour satisfaire le critère principal a été atteint. Les résultats de cette étude seront présentés lors du prochain congrès de la Société Européenne d’Oncologie Médicale (ESMO), en septembre 2015.

Basé sur le profil favorable d’innocuité et d’efficacité observé lors d’études cliniques précédentes, le Lutathera(R) est actuellement autorisé en usage compassionnel dans 9 pays européens (Autriche, Danemark, Estonie, Finlande, Grèce, Espagne, Portugal, Suisse et Royaume-Uni) lorsqu’aucune alternative thérapeutique n’est disponible et est disponible dans le cadre d’une ATU dite de cohorte en France.

A propos des TNE

Les tumeurs neuroendocrines (TNE) représentent un groupe de tumeurs originaires des cellules neuroendocrines de l’organisme. Les TNE peuvent rester « silencieuses » sur le plan clinique pendant des années, retardant ainsi leur diagnostic auprès d’un grand nombre de patients. Ces cancers sont rares mais constituent le deuxième type de cancer gastro-intestinal le plus répandu et leur incidence est en hausse.

Nous estimons que l’incidence des TNE de l’intestin moyen est aujourd’hui d’environ 47.300 patients au total aux États-Unis et en Union européenne.

Les TNE sont classées comme maladies orphelines par les autorités européennes et américaines, ce qui signifie qu’elles affectent une population relativement faible de personnes dans les pays concernés. Aux États-Unis, les médicaments orphelins sont définis comme médicaments utilisés pour traiter des maladies ou affections qui touchent moins de 200.000 personnes sur leur territoire. Dans l’Union européenne, les médicaments orphelins sont définis comme des médicaments qui traitent les maladies ou affections touchant moins de cinq personnes pour 10.000.

A propos de Lutathera(R) et des essais cliniques en cours

Lutathera(R) (ou 177Lu-DOTATATE) est un peptide analogue de la somatostatine marqué au Lu-177 actuellement en phase de développement pour le traitement des tumeurs neuroendocrines gastro- entéro-pancréatiques (TNE-GEP). Ce nouveau médicament a reçu la désignation de médicament orphelin de la part de l’Agence Européenne des Médicaments (EMA) et de la Food and Drug Administration (FDA) aux USA. Ce statut accorde au Lutathera(R) une extension de la protection du brevet post-commercialisation pour une période de 7 ans aux Etats-Unis et de 10 ans en Europe. Le Lutathera(R)est aujourd’hui autorisé en usage compassionnel dans dix pays européens lorsqu’aucune alternative thérapeutique n’est disponible et avec autorisation spéciale.

Lutathera(R) appartient à une famille émergente de traitements appelés peptide receptor radionuclide therapy (PRRT) qui ciblent les tumeurs carcinoïdes à l’aide de peptides analogues à la somatostatine marqués radioactivement.

Il existe un réel manque dans l’arsenal thérapeutique pour traiter efficacement les TNE inopérables avancées. En effet il n’existe à l’heure actuelle aucun traitement approuvé pour les TNE autres que pancréatiques (environ 10% des TNE sont d’origine pancréatique) progressant sous analogues à la somatostatine. Actuellement en étude clinique de phase III avec l’étude clinique pivot NETTER-1, Lutathera(R) est le candidat en développement le plus avancé des PRRT.

NETTER-1 est une étude de Phase III, multicentrique, internationale, randomisée, en groupes parallèles, contrôlée par un traitement de référence, destinée à évaluer l’efficacité et la sécurité de Lutathera(R) par rapport à une double dose d’Octréotide LAR chez les patients atteints de tumeurs carcinoïdes de l’intestin moyen (TNEs de l’intestin moyen) inopérables, qui surexpriment les récepteurs de la somatostatine et progressent sous traitement avec Octréotide LAR. Le critère principal est l’évaluation de la survie sans progression (PFS). Les critères secondaires incluent l’innocuité, le taux de réponse objective, le délai de progression tumorale, la survie globale et la qualité de vie. L’étude est menée dans 51 centres cliniques aux Etats-Unis et en Europe. Le recrutement a été finalisé en février 2015 et 74 événements de progression sont requis pour atteindre le critère principal d’évaluation. Lutathera(R) a pour objectif de répondre à un vide dans l’arsenal thérapeutique, car après progression sous analogues “froids” de la somatostatine tels que l’Octréotide LAR (Novartis) ou la Somatuline (Ipsen), il n’y a pas de traitements alternatifs approuvés dans cette indication.

A propos de Advanced Accelerator Applications

Advanced Accelerator Applications (AAA), groupe radiopharmaceutique fondé en 2002, dispose d’une vaste expérience dans le développement de produits innovants et d’applications à visée thérapeutique et diagnostique, et se focalise plus particulièrement sur les domaines de l’imagerie moléculaire et de la médecine personnalisée. A ce jour, AAA compte 17 laboratoires de production et de R&D et emploie plus de 350 salariés répartis dans 11 pays (France, Italie, Royaume-Uni, Allemagne, Suisse, Espagne, Pologne, Portugal, Israël, Etats-Unis et Canada). En 2014, les ventes de AAA se sont élevées à €69.9 millions d’euros (+29.8% vs. 2013). Pour de plus amples informations sur AAA, veuillez visiter le site www.adacap.com.

A propos de la Médecine Nucléaire Moléculaire (MNM)

La Médecine Nucléaire Moléculaire (MNM) est une spécialité médicale qui utilise des quantités infimes de substances actives, appelées radiopharmaceutiques, pour créer des images d’organes et de lésions et traiter un certain nombre de maladies, comme le cancer. Des produits radiopharmaceutiques sont injectés dans l’organisme et se fixent de façon ciblée sur des organes ou lésions choisis pour révéler des processus biochimiques spécifiques.

Le Diagnostic Nucléaire Moléculaire permet aux médecins de diagnostiquer avec précision des maladies complexes comme le cancer, les maladies cardiovasculaires et des troubles neurologiques à des stades précoces et d’en améliorer le suivi. Les patients sont injectés au traceur radiopharmaceutique et des images avec des caméras TEP (Tomographie par Emission de Positons) ou TEMP (Tomographie par Emission Mono-Photonique) sont produites.

Le terme théranostique est aujourd’hui utilisé pour définir des tests diagnostiques, dit “compagnons.” Cela signifie qu’un médicament thérapeutique est développé et est approuvé pour être utilisé conjointement avec un test de diagnostic. Le médicament diagnostic permet de savoir à l’avance si le traitement est adapté pour une maladie donnée chez un patient et s’il sera efficace, augmentant ainsi la rentabilité de l’ensemble du traitement. La Médecine Nucléaire Moléculaire donne tout son sens au mot «théranostique», car elle permet d’associer diagnostic et thérapie dans un même médicament. C’est une discipline qui joue un rôle clef dans la transition d’une médicine globale vers une médicine personnalisée.

Décharge

Le présent communiqué peut contenir des déclarations de nature prospective. Toutes les déclarations, autres que les déclarations de faits historiques, contenues dans ce communiqué de presse, y compris des déclarations concernant la stratégie de l’entreprise, les opérations futures, la situation financière future, les revenus futurs, les coûts projetés, perspectives, plans et objectifs de gestion, sont des déclarations de nature prospective. Les mots «anticipe», «croit», «estime», «s’attend à», «a l’intention de», «peut», «planifie», «prévoit», «projette», «cible», «potentiel», «sera», «serait», «pourrait», «devrait», «continue» et autres expressions similaires visent à identifier des déclarations de nature prospective, même si certaines déclarations prospectives ne contiennent pas ces mots précis. Les déclarations prospectives reflètent les attentes actuelles de la société quant aux événements futurs. Ces déclarations prospectives comportent des risques et des incertitudes ainsi que d’autres facteurs qui pourraient rendre les résultats réels notablement différents des résultats, performances ou réalisations futurs annoncés ou impliqués dans ces déclarations. Ces facteurs comprennent, mais ne sont pas limités à, l’évolution des conditions du marché, la conclusion fructueuse et en temps opportun des études cliniques, l’approbation de l’EMA, de la FDA et autres approbations réglementaires pour nos produits en développement, l’établissement d’alliances commerciales, l’impact de la concurrence en terme de produits et de prix, le développement de nouveaux produits, et les incertitudes liées au processus d’approbation réglementaire ou la capacité d’obtenir des produit pharmaceutiques en quantité suffisante ou à des normes acceptables pour les autorités réglementaires de santé pour compléter les essais cliniques ou pour répondre à la demande commerciale. AAA fournit les informations contenues dans le présent communiqué de presse à la date d’aujourd’hui et n’est pas tenu de mettre à jour les déclarations prospectives y figurant au vu de nouvelles informations, de futurs événements ou autres, à moins que les lois sur les valeurs mobilières applicables le requièrent.

Contacts

AAA Relations Presse
Laetitia Defaye
Head of Corporate Communications
laetitia.defaye@adacap.com
Tel: +33 (0)6 86 65 73 52

Véronique Mermet
Communications Officer
info@adacap.com
Tel: +33 (0)4 50 99 30 70

AAA Relations Investisseurs

Jordan Silverstein
Director of Investor Relations
jordan.silverstein@adacap.com
Tel: + 1-212-235-2394

Contacts Médias

FTI Consulting (UK)
Julia Phillips
Julia.Phillips@fticonsulting.com
Tel: +44 (0)203 727 1000

Natalie Garland-Collins
Natalie.Garland-Collins@fticonsulting.com
Tel: +44 (0)203 727 1000

iCorporate (Italy)
Elisa Piacentino
elisa.piacentino@icorporate.it
Tel: +39 02 4678754 – +39 366 9134595

JV Public Relations NY (US)
Janet Vasquez
jvasquez@jvprny.com
Tel: + 1-212- 645-5498

SOURCE: Advanced Accelerator Applications

ReleaseID: 430261

Van Halen Tickets: CapitalCityTickets.com is Cutting Their Prices on Van Halen Concert Tickets for their 2015 Summer Tour Dates for Cities like Seattle, Morrison, and St. Louis

Van Halen concert tickets for their 2015 summer North American tour dates are on sale now for cities like Seattle, Morrison, and St. Louis. Secondary ticket market provider CapitalCityTickets.com is providing Van Halen fans with a promo code CITY5 to save 5% on all orders.

CapitalCityTickets.com carries a wide selection of Van Halen concert tickets at affordable prices. Van Halen is hitting the road in the summer of 2015 and kicking it all off on July 5^th in Seattle, WA. The tour will hit nearly 40 cities.

Don’t miss your opportunity to see Van Halen live in concert playing all the hits such as “Runnin’ With the Devil” and “Panama”. David Lee Roth will be fronting the band.

The Kenny Wayne Shepherd Band will be joining in support.

The band will be out supporting their new album, Tokyo Dome Live in Concert.

CLICK HERE to browse all levels of seating for Van Halen concerts at CapitalCityTickets.com

There isn’t an event you will see this year that has the same exciting atmosphere as a live Van Halen concert. Be one of the fortunate few who get to attend a Van Halen show this year.

Save on already slashed ticket prices by using promo code CITY5 to save an additional 5% on each order.

Follow on Social Media for Special Deals and Discounts.

Facebook: http://www.facebook.com/CapitalTickets
Twitter: http://www.twitter.com/CapitalTix

2015 Van Halen North American Tour Dates

7/5 – Seattle, WA at White River Amphitheatre
7/7 – Portland, OR at Amphitheater Northwest
7/9 – Concord, CA at Concord Pavilion
7/11 – San Bernardino, CA at San Manuel Amphitheater
7/14 – Irvine, CA at Verizon Wireless Amphitheatre
7/16 – Mountain View, CA at Shoreline Amphitheatre
7/18 – Salt Lake City, UT at USANA Amphitheatre
7/20 – Morrison, CO at Red Rocks Amphitheatre
7/22 – Bonner Springs, MO at Cricket Wireless Amphitheater
7/24 – Chicago, IL at First Midwest Bank Amphitheatre
7/26 – St. Louis, MO at Hollywood Casino Amphitheatre
7/28 – Burgettstown, PA at First Niagara Pavilion
7/30 – Bangor, ME at Darling’s Waterfront Pavilion
8/1 – Mansfield, MA. at Xfinity Center
8/3 – Cuyahoga Falls, OH at Blossom Music Center
8/5 – London, Ontario at Western Fair District
8/7 – Toronto, Ontario at Molson Canadian Amphitheatre
8/9 – Holmdel, NJ at PNC Bank Arts Center
8/11 – Hartford, CT at Xfinity Center
8/13 – Wantagh, NY at Nikon At Jones Beach Theater
8/23 – Hershey, PA at Hershey Park
8/25 – Darien Center, NY at Darien Lake Performing Arts Center
8/27 – Camden, NJ at Susquehanna Bank Center
8/29 – Bristow, VA at Jiffy Lube Live
8/31 – Cincinnati, OH at Riverbend Music Center
9/2 – Noblesville, IN at Klipsch Music Center
9/4 – Clarkston, MI at DTE Energy Music Theatre
9/6 – Bethel, NY at Bethel Woods Center for the Arts
9/9 – Raleigh, NC at Walnut Creek Amphitheater
9/11 – Charlotte, NC at PNC Music Pavilion
9/13 – Tampa, FL at MIDFLORIDA Credit Union Amphitheatre
9/15 – West Palm Beach, FL at Coral Sky Amphitheatre
9/17 – Birmingham, AL at Oak Mountain Amphitheatre
9/21 – Austin, TX at Austin360 Amphitheater
9/23 – Dallas, TX at Gexa Energy Pavilion
9/25 – Houston, TX at Cynthia Woods Mitchell Pavilion
9/28 – Phoenix, AZ at Ak-Chin Pavilion
9/30 – Chula Vista, CA at Sleep Train Amphitheatre
10/2,4 – Los Angeles, CA at Hollywood Bowl

CapitalCityTickets.com
Live Customer Support
Order By Phone Toll Free 7 Days a Week
(855) 514-5624

Browse the inventory of tickets for Van Halen at CapitalCityTickets.com today and save! http://www.capitalcitytickets.com/Van-Halen-Tickets

Disclaimer: CapitalCityTickets.com is not associated with any artists, teams, venues, organizations, institutions, bands, or artists featured on their website in any way. Also, any names or titles used in this press release are solely for descriptive purposes and do not imply, indicate, or suggest any type of affiliation, partnership, or endorsement.

CapitalCityTickets.com is a reliable online marketplace serving the secondary market with tickets for all major concerts, sports, and theatre events. Online shoppers can take advantage of Promo Code “CITY5” while tickets last.

Check out the discount codes online for all upcoming events. CapitalCityTickets.com keeps low overheads which allow this trusted ticket site to keep prices competitive

CapitalCityTickets.com | Live Customer Support | Order By Phone Toll Free | 7:00am-1:00am EST | (855) 514-5624

Logo: http://www.abnewswire.com/pressreleases/wp-content/uploads/2015/06/1435002701.jpeg

“Buy Van Halen Concert Tickets Online at CapitalCityTickets.com with Promo Code”

Media Contact
Company Name: CapitalCityTickets.com
Contact Person: Media Relations
Email: customerservice@capitalcitytickets.com
Phone: 1-855-514-5624
Country: United States
Website: http://www.capitalcitytickets.com/Van-Halen-Tickets

Source: ABNewswire

ReleaseID: 31556

Thermaltronics Manufacturer of Soldering Technology Partners with RS Components

Thermaltronics and RS Components have announced a new strategic partnership that will expand distribution of the unique advanced soldering technology, “Curie Heat” (CHT) on a global basis. RS Components is one of the world’s largest distributors of electronics and maintenance products.

Hong Kong, China – June 30, 2015 /PressCable/ —

Thermaltronics‘ is a manufacturer of advanced soldering stations that employ Curie Heat Technology. This unique technology optimizes heat transfer ensuring increased performance, productivity and quality. Curie Heat Technology is different, it responds to the thermal demands of each solder joint by adjusting the power instantaneously, thereby meeting the exact requirements of the substrate component and solder material.

Unlike conventional soldering systems, Curie Heat Technology ensures there is no overshoot of tip temperature, making it ideal for precise electronic PCB assembly and SMT rework. Longer tip life and increased productivity can also be achieved through use of the “sleep” workstand, which “powers down” the tip when not in use. Delivered Power is controlled by the physical properties of the heater which is made of a proprietary ferromagnetic alloy to control the Curie Point temperature.

Michael Gouldsmith, Director, had this to say about the new Partnership: “Thermaltronics Soldering Systems are trusted, proven and are used by some of the largest manufacturers of avionics, electronics, medical & technology companies in the world. Partnering with RS Components will enable us to expand our distribution throughout Europe and globally, thereby providing customers with the finest in soldering technology.”

Additionally, Michael said, “Advances in plating technology have also ensured reductions in the “cost of ownership” and extended tip life. With today’s delicate and complex electronic assemblies, temperature accuracy is a consistent challenge. Component density, lead size and thermally sensitive components all combine to increase process control demands, criteria which many systems fail to meet. To aid in the selection of the correct temperature profile, solder cartridges are color coded for easy identification. This unique and patented feature has additional benefits in both inventory management and quality control.”

As part of this partnership, RS is supporting Themaltronics’ plan for business growth by providing additional distribution markets for it’s cutting edge soldering products. Customers purchasing these products via the global RS websites will benefit from over 60 websites across the world and easy online access to useful supplementary information, including videos and technical data, via the web and mobile platforms.

About RS Components: RS Components, are the global distributor for engineers. With operations in 32 countries, around 500,000 products are offered through the internet, catalogs and at trade counters to over one million customers, shipping more than 44,000 parcels a day. Live Chat is available in 29 Countries in 19 languages across the world. Products sourced from 2,500 leading suppliers, include semiconductors, interconnect, passives and electromechanical, automation and control, electrical, test and measurement, tools and consumables.

For more information about us, please visit http://www.thermaltronics.com

Contact Info:
Name: Ariel Wang
Email: info@thermaltronics.com
Organization: Thermaltronics (HK) Co LTD

Release ID: 85660

Rock The Stock Shows Its Increasing Popularity Among Best Binary Options Brokers

Rock The Stock is an incredible binary options software that is for a very limited time, free to join and there is no credit card required. It is 100% safe and offers visual step by step guide and guarantee 80% success rate.

New York, United States – June 30, 2015 /PressCable/ —

Rock the Stock is one of the best binary options trading sites in existence. More specifically, it is a place where those trading in such options can go to see which binary stocks are performing the best and make one’s investments accordingly. Binary options, it is true, are the simplest type of investment insofar as there are only two possible outcomes — cash or another asset in full, or nothing. Because of this, the investor need not have detailed knowledge of the stock market to trade in binaries.

Click Here To Get Instant Access To Rock The Stock Through Official Website

Useful Information On The Website

At any given time, there will be more than three videos on the website, arranged from top to bottom in reverse chronological order. Each lasts for slightly over three-and-a-half minutes and gives information like where the new trades are and where the investor’s account currently stands. The user can pull up a table with his or account that gives:

Positions, both open and closed includes an ID number for each option asset type, whether it is a call or put option, start and expiry times and amount invested. The system also shows deposits, withdrawals, banking history, personal information and regulation.

A few hours separate the sessions in each video, during which time at least some things have changed.

Next to each video is a set of three businesses on which binaries have been placed; they include Facebook, Google, Coca-Cola, Amazon, and Alibaba. Above are the date of the video and the profit for the day. In a dark yellow box is a set of “comments for the day” in which members tell how their investments went. For example, investors may relate how some uncertainty caused some of their stocks to lose value, what they found most impressive about stock performances and how things went overall.

Lifetime License Promotion

This is Rock the Stock’s software program, which can be downloaded to the user’s PC. Normally, it is available only for a 45-day risk-free trial download, after which the user if he or she wishes to keep it, must pay the full price. Right now, however, the company is holding a special June 2015 promotion, whereby new members receive a lifetime license at no cost. The developer of the software has said that “The software is currently reaching successful trade percentages that are unmatched by any other tools that are available and it’s all thanks to the sophisticated code that drives the entire system.”

Read Testimonials Of Real Users and Sign Up Free To Download For Limited Time Only

More About This Binary Options Software

As with many stock trading companies, there are some who claim that Rock the Stock is a scam. There are many success stories online and it is one of the most legitimate binary options software; people reports that the software has been generating profits for them ever since they downloaded it and that they have had a great experience.y have had a great experience.

For more information about us, please visit http://quickcashsystemz.com/

Contact Info:
Name: Cooper Belmont
Organization: RockTheStock
Phone: 5167841034

Release ID: 85655

Mobile App for Construction Industry Promises Better Labor Management

busybusy releases five previously unpublished facts about its upcoming busybusy app launch. Further information can be found at www.busybusy.com.

St. George, UT, USA – June 30, 2015 /PressCable/ —

Ahead of the launch of its new mobile time card app for the construction industry, busybusy is making public information about the busybusy app set to go live July 15th, which fans and consumers within the construction management space will find interesting…

The information include nuggets such as how:

The idea for creating busybusy came about when in 2009 the Founder, Isaac, had just filed bankruptcy for his excavation company. He learned he wasn’t alone, as 70% of construction firms fail within the first 7 years…

The busybusy app, for smartphones, has been in development for 5 years with a team of 20 developers working on it, which is considered large by industry standards. This goes to show great things can happen from the ashes of losing everything. Isaac’s goal is to help the industry improve their profitability using technology.

The busybusy vision almost didn’t see the light of day, when almost a years worth of development had to be thrown out after learning the construction industry wasn’t embracing a social platform to perform for business management. The problem was overcome by changing company direction to a labor budget management platform using a mobile app.

busybusy has done something different compared to other businesses in the constructing labor time management space, by inviting several construction companies to use the software for free in their business during development. Many of those companies have seen rising profit and productivity as a result of the busybusy mobile app.

The busybusy app has been released as part of busybusy’s greater plans to give the construction industry the tools they need to make profitable decisions based off of real-time information. This includes the already available labor budget management, and the developing asset management. It’s hoped this goal will be achieved by end of the second quarter of 2016

busybusy got their start when Founder Isaac Barlow noticed a growing need for technology in labor cost management in construction. With 20 years prior experience in the constructing labor time management world, Isaac Barlow decided to go ahead and start in 2009.

Isaac Barlow is quoted saying: “We like to do things to connect with our consumers and customers. Things like meet with them in person, work with their employees, provide customer support with online webinars and chat, and telephone support, and releasing these little factoids ahead of the busybusy app launch are what make a difference.”

busybusy is set to launch their improved platform July 15th. To find out more, it’s possible to visit www.busybusy.com

For more facts and further information about busybusy, this can be discovered at www.busybusy.com

For more information about us, please visit http://www.busybusy.com

Contact Info:
Name: Herbert Timpson
Email: herbert@busybusy.com
Organization: busybusy
Address: 446 S Mall Dr, St. George, UT 84790
Phone: 855.287.9287

Release ID: 83558

Food Additives Industry 2015 – Global and China Food Additives Market 2014: Acute Market Reports

AcuteMarketReports.com has announced the addition of “Food Additives Industry 2015” market research report to their database

Pune, India – June 30, 2015 /MarketersMedia/ —

Global Food Additives Industry 2015 Market Research Report

2015 Global Food Additives Industry Report is a professional and in-depth research report on the world’s major regional market conditions of the Food Additives industry, focusing on the main regions (North America, Europe and Asia) and the main countries (United States, Germany, Japan and China).

The report firstly introduced the Food Additives basics: definitions, classifications, applications and industry chain overview; industry policies and plans; product specifications; manufacturing processes; cost structures and so on. Then it analyzed the world’s main region market conditions, including the product price, profit, capacity, production, capacity utilization, supply, demand and industry growth rate etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Global and China Food Additives Industry 2014 Market Research Report

The report firstly introduced Food Additives basic information included Food Additives definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis and influence, Food Additives industry policy and plan, Food Additives product specification, manufacturing process, product cost structure etc. then statistics Global and China key manufacturers Food Additives capacity production cost price profit production value gross margin etc details information, at the same time, statistics these manufacturers Food Additives products customers application capacity market position company contact information etc company related information, then collect all these manufacturers data and listed Global and China Food Additives capacity production capacity market share production market share supply demand shortage import export consumption etc data statistics, and then introduced Global and China Food Additives 2009-2019 capacity production price cost profit production value gross margin etc information.

And also listed Food Additives upstream raw materials equipments and down stream clients survey analysis and Food Additives marketing channels industry development trend and proposals. In the end, The report introduced Food Additives new project SWOT analysis Investment feasibility analysis investment return analysis and also give related research conclusions and development trend analysis on Global and China Food Additives industry.

Browse All Reports of This Category @ http://www.acutemarketreports.com/category/catering-market

About Acute Market Reports

Acute Market Reports is the most sufficient collection of market intelligence services online. Acute Market Reports provide online reports from over 100 best publishers and upgrade Acute Market Reports collection regularly to offer direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends. Acute Market Reports database consists of 200,000+ market research reports with detailed & minute market research.

For more information about us, please visit http://www.acutemarketreports.com/

Contact Info:
Name: Chris Paul
Email: sales@acutemarketreports.com
Organization: Acute Market Reports
Address: Office No 1, 1st Floor , Aditi Mall, Baner, Pune, MH, 411045 India
Phone: 1-855-455-8662

Source: http://marketersmedia.com/food-additives-industry-2015-global-and-china-food-additives-market-2014-acute-market-reports/85664

Release ID: 85664

Santa Barbara to Commence Trading on NEX

VANCOUVER, BC / ACCESSWIRE / June 30, 2015 / Santa Barbara Resources Limited (TSX VENTURE: SBL – “Santa Barbara” or the “Company”) reports that following a review by the TSX Venture Exchange (the “Exchange”), the Exchange has determined that the Company has not maintained the Exchange’s continued listing requirements because of the Company’s continuing deficiency relating to working capital and classification as a junior natural resource mining company, and as a result the Company’s shares have been transferred from Tier 2 of the Exchange to the NEX Board.

NEX is a separate board of the Exchange and it provides a trading platform for listed companies that have fallen below the Exchange’s ongoing listing standards.

The Company’s shares will be posted for trading at the opening on Thursday, July 2, 2015 under the symbol SBL.H.

As announced on November 19, 2014, the Company granted an option (“ERCED Option“) to purchase all of the shares of the Company’s wholly owned subsidiary, Santa Barbara Resources Peru S.A.C. (“SBL Peru“), the holder of the Sancos and Surapata gold projects in Peru to ERCED S.A.C., (“ERCED“) a privately owned Peruvian mineral exploration and mining company.

The Company has received both shareholder and regulatory approval of the ERCED Option. Final completion of the sale is pending final clearance from Peruvian tax authorities. On February 25, 2015, the Company and ERCED entered into an agreement whereby ERCED agreed to assume the Company’s corporate social responsibility payment of what is now 147,000 Soles (approximately US$46,408) and to deduct the amount from the final purchase price payment of US$615,000 to be paid to the Company on closing.

About the Company

Santa Barbara is a South American mineral explorer focusing on South America, and Peru in particular. The Company has 25.3 million shares outstanding. It is expected that the proposed sales transaction, if completed, will provide the Company with sufficient working capital to continue its mineral property acquisition and exploration activities for at least 12 months.

ON BEHALF OF THE BOARD

“Christoph Lassl”
_______________________________
Christoph Lassl, President and
Chief Executive Officer

Please visit the Company’s web site: www.sbr-ltd.com. For further information, please contact Christoph Lassl, President and Chief Executive Officer. Telephone: 604-536-2711 or email: christoph@sbr-ltd.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains certain statements that may be deemed “forward-looking” statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur and include, without limitation, statements regarding the Company’s plans with respect to selling its mineral properties and obtaining the proceeds therefrom. Although Santa Barbara believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements due to factors such as uncertainties in obtaining required approvals or in completing a transaction in difficult market conditions. Forward looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by law, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

SOURCE: Santa Barbara Resources Limited

ReleaseID: 430252

AAA Signs Distribution Agreement for Lutathera in Japan with FUJIFILM RI Pharma, Co., LTD

SAINT-GENIS-POUILLY, FRANCE / ACCESSWIRE / June 30, 2015 / Advanced Accelerator Applications S.A. (“AAA” or “the Company”), an international specialist in Molecular Nuclear Medicine (MNM), announces that it has entered into a distribution agreement for Lutathera in Japan with FUJIFILM RI Pharma, Co., LTD (“FRI”), a leading in-country distributor of nuclear medicine and diagnostic imaging products. Lutathera is currently in a pivotal Phase III trial, both in the US and EU, with results expected in Q3.

As part of the agreement, AAA will receive launch and development milestone payments, in addition to royalties on product sales. Lutathera will be manufactured by AAA in Europe and sold to FRI by its subsidiary AAA International.

AAA and FRI will work together to meet all Japanese regulatory requirements and prepare for national approval.

“We are pleased to have signed our first distribution agreement for Lutathera in Asia with FRI,” said Stefano Buono, Chief Executive Officer of AAA. “FRI provides important sales, marketing and distribution capabilities for Lutathera in the Japanese market as well as providing the support needed to gain regulatory clearance in Japan. We believe Asia is a significant market for Lutathera, and Japan represents an important first presence as we introduce the product into the region. Our plans are to continue implementing selected distributorships such as our agreement with FRI, in countries where we have not planned a direct presence.”

“In Europe’s five key markets and the US, AAA’s plan is to build complete and dedicated commercial structures in each country to support the launch and promotion of Lutathera and Somakit, Lutathera’s companion diagnostic, for which a New Drug Application (NDA) will soon be submitted to the FDA,” added Stefano Buono.

Gérard Ber, Chief Operating Officer of AAA, commented: “Meeting an unmet medical need with Lutathera for gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients around the world is a key strategic objective of AAA. As we start developing the Lutathera franchise, we look forward to additional commercialization agreements for other countries and the ability to provide cancer patients with better care on an increasingly global scale.”

Lutatherais currently in a pivotal Phase III trial for the treatment of midgut NETs in 51 clinical centers in the United States and EU (the NETTER-1 clinical study). Enrollment was completed in February 2015 and the number of events necessary to meet the primary endpoint has been reached. The results of the NETTER-1 trial for Lutathera will be presented during the ESMO meeting in September 2015.

Based on current evidence of efficacy and safety, Lutathera is already available in 9 European countries (Austria, Denmark, Estonia, Finland, Greece, Portugal, Spain, Switzerland and the UK) under compassionate use or named patients programs and in France under a Cohort Temporary Authorization of Use (ATU de Cohorte).

About NETs

Neuro Endocrine Tumors, also known as NETs, are a group of tumors originating in the neuroendocrine cells of many different organs. NETs can remain clinically silent for years delaying the diagnosis in a large number of patients. These cancers are rare but, for example, they are the second most common type of gastrointestinal malignancy and their incidence is increasing.

The estimated incidence of NETs for the combined populations of the United States and the European Union is approximately 47,300.

NETs are classified as orphan diseases by European and U.S. regulatory authorities, meaning that they affect a relatively small population of individuals in the relevant jurisdiction. In the United States, orphan drugs are defined as drugs that treat diseases or conditions that affect 200,000 or fewer individuals in the country. In the European Union, orphan drugs are defined as drugs that treat diseases or conditions that affect fewer than five out of 10,000 individuals in the European Union.

About Lutathera and ongoing clinical trials

Lutathera (or 177 Lu-DOTATATE) is a Lu-177-labeled somatostatin analogue peptide currently under development for the treatment of Gastro-Entero-Pancreatic Neuro Endocrine Tumors (GEP-NETs). This novel compound has received orphan drug designation from the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), which provides post market authorization exclusivity in the US (7 years), and Europe (10 years). It has been approved for treatment of all NETs on a compassionate use and named patient basis in ten European countries.

Lutathera belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT) which involves targeting carcinoid tumors with radiolabeled somatostatin analogue peptides.

There is a real unmet medical need for an effective treatment of inoperable, advanced NETs and there are currently no therapeutic options available for patients with NETs other than pancreatic (about 10% of NETs are pancreatic) who are progressive under somatostatin analogues. Currently at the end of its Phase III development with the NETTER-1 pivotal study, Lutathera is the most advanced candidate in development for PRRT.

NETTER-1 is an international, multi-center, randomized, Phase III study comparing treatment with Lutathera to a double dose of Octreotide LAR in patients with inoperable, progressive under Octreotide LAR treatment, midgut carcinoids (midgut NETs) overexpressing somatostatin receptors. The primary endpoint of the trial is the assessment of progression-free survival. Secondary endpoints include safety, objective response rate, time to tumor progression, overall survival and quality of life. The study is conducted in 51 clinical centers in the United States and Europe. Enrollment was completed in February 2015 and 74 events are expected to meet the primary endpoint. Lutathera is aiming at covering an unmet medical need, as after progression from “cold” analogues of somatostatin such as Octreotide LAR (Novartis) or Somatuline (Ipsen), there are no alternative therapies approved in this indication.

About Advanced Accelerator Applications

Advanced Accelerator Applications (AAA) is a radiopharmaceutical company founded in 2002 to develop innovative diagnostic and therapeutic products. AAA’s main focus is in the field of Molecular Imaging and targeted, individualized therapy for the management of patients with serious conditions (“Personalized Medicine”). AAA currently has 17 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 350 employees in 11 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, Israel, U.S. and Canada). In 2014 AAA reported sales of €69.9 million (+29.8% vs. 2013). For more information please visit: www.adacap.com.

About Molecular Nuclear Medicine (“MNM”)

Molecular Nuclear Medicine is a medical specialty using trace amounts of active substances, called radiopharmaceuticals, to create images of organs and lesions and to treat various diseases, like cancer. The technique works by injecting targeted radiopharmaceuticals into the patient’s body that accumulate in the organs or lesions that reveal specific biochemical processes. Molecular Nuclear Diagnostics employs a variety of imaging devices and radiopharmaceuticals. PET (Positron Emission Tomography) and SPECT (Single Photon Emission Tomography) are highly sensitive imaging technologies that enable physicians to diagnose different types of cancer, cardiovascular diseases, neurological disorders and other diseases in their early stages.

Theragnostics is today used to define “companion drugs.” This means that a therapeutic drug is developed and is approved to be used together with a diagnostic test. The test can tell you if the drug is suitable for a specific disease in a specific patient and checks if the treatment could be effective, thus increasing the cost-effectiveness of the whole treatment. MNM can integrate diagnostics and therapeutics properties into a single theragnostic drug and is a key discipline in the transition from population-based medicine to Personalized Medicine.

Cautionary Statement Regarding Forward-Looking Statements

This press release may contain forward-looking statements. All statements, other than statements of historical facts, contained in this press release, including statements regarding the Company’s strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements reflect the Company’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, EMA, U.S. FDA and other regulatory approvals for our product candidates, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process or the ability to obtain drug product in sufficient quantity or at standards acceptable to health regulatory authorities to complete clinical trials or to meet commercial demand. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

AAA Media Relations
Laetitia Defaye
Head of Corporate Communications
laetitia.defaye@adacap.com
Tel: +33 (0)6 86 65 73 52